Arvinas Inc.
Betting protein degradation will beat mere inhibition
This article was originally published in Start Up
Executive Summary
Arvinas Inc. believes it has found a better approach to drug development: instead of inhibiting proteins, the start-up aims to degrade and remove them from the system entirely. The company will exploit two technology platforms developed at Yale University, both of which provide ways of marking specific proteins for destruction by normal cellular mechanisms.